A Phase 2 interventional study of Levomilnacipran ER and Paroxetine, Sertraline, Citalopram or Fluoxetine. in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-06.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 11th largest by enrollment, is one of 2 that started in 2011, is the only one in phase 2, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →
Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 262 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 472 across the 14 interventional studies. Of the 14 that completed or were terminated, 12 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
53 studies in Depressive Disorder, Major by AbbVie: 1 open now, 1 under way, none of them phase 3. Of 50 finished, 37 (74%) have results posted.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 35th largest by enrollment, is one of 7 that started in 2011, is one of 12 in phase 2, and was the 16th registered.
AbbVie’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 53 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy, safety and tolerability of Levomilnacipran ER for the treatment of fatigue associated with major depressive disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history of meeting criteria for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 -120 mg/day Levomilnacipran ER capsules, oral administration
Drug: Levomilnacipran ER
Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
Drug: Paroxetine, Sertraline, Citalopram or Fluoxetine.
Matching placebo capsules, oral administration
Drug: Placebo
Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
Matching placebo capsules, oral administration, once daily dosing
Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued
Time frame: From Baseline to Week 8
Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue.
Time frame: From Baseline to Week 8
Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent).
Time frame: From Baseline to Week 8
Patients were recruited over a 12-month period from April of 2011 to April of 2012 at 20 studies sites in the United States.
| Milestone | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| Started | 93 | 90 | 79 |
| Safety population | 89 | 85 | 77 |
| Completed | 71 | 72 | 62 |
| Not completed | 22 | 18 | 17 |
| Withdrew: Adverse event | 6 | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 7 | 3 |
| Withdrew: Withdrawal by subject | 4 | 2 | 4 |
| Withdrew: Lost to follow-up | 10 | 6 | 5 |
| Withdrew: Other reasons | 0 | 0 | 2 |
The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued
| units on a scale | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score | -1.5 ± 1.3 | -1.8 ± 1.4 | -1.9 ± 1.4 |
The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent).
| units on a scale | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward | -5.9 ± 7.9 | -7.0 ± 7.3 | -6.4 ± 7.0 |
The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue.
| units on a scale | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score | -1.4 ± 1.5 | -1.7 ± 1.5 | -1.7 ± 1.5 |
Collected over Adverse event data occurred over a 16-month period from April of 2011 to September of 2012 at 20 studies sites in the United States.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/89 (0%) | 39/89 (43.8%) |
| Levomilnacipran ER | — | 1/85 (1.2%) | 41/85 (48.2%) |
| SSRI | — | 0/77 (0%) | 37/77 (48.1%) |
| Event | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/89 | 1/85 | 0/77 |
| Event | Placebo | Levomilnacipran ER | SSRI |
|---|---|---|---|
| NauseaGeneral disorders | 4/89 | 14/85 | 6/77 |
| HeadacheNervous system disorders | 14/89 | 12/85 | 6/77 |
| Dry mouthGastrointestinal disorders | 6/89 | 8/85 | 9/77 |
| DiarrhoeaGastrointestinal disorders | 8/89 | 4/85 | 9/77 |
| Upper respiratory tract infectionInfections and infestations | 7/89 | 0/85 | 3/77 |
| SomnolenceNervous system disorders | 4/89 | 3/85 | 6/77 |
| DizzinessNervous system disorders | 2/89 | 6/85 | 1/77 |
| Heart rate increasedInvestigations | 3/89 | 6/85 | 0/77 |
| InsomniaPsychiatric disorders | 1/89 | 2/85 | 5/77 |
| AnxietyPsychiatric disorders | 1/89 | 1/85 | 5/77 |
A total of 262 patients were randomized to receive double-blind treatment. The Baseline Participant population is based on the 251 randomized patients received at least 1 dose of double-blind treatment (Safety Population).
| Age, Continuous(years) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| Mean | 41.4 ± 12.0 | 42.9 ± 12.6 | 42.8 ± 11.3 | 42.3 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| Female | 58 | 49 | 49 | 156 |
| Male | 31 | 36 | 28 | 95 |
| Race/Ethnicity, Customized(participants) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| White | 62 | 57 | 47 | 166 |
| Black or African American | 26 | 25 | 25 | 76 |
| Asian | 1 | 3 | 2 | 6 |
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(participants) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 10 | 22 |
| Not Hispanic or Latino | 81 | 81 | 67 | 229 |
| Region of Enrollment(participants) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| United States | 89 | 85 | 77 | 251 |
| Weight(kg) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| Mean | 79.95 ± 15.27 | 82.23 ± 18.14 | 83.31 ± 17.61 | 81.75 ± 17.00 |
| Body Mass Index (BMI)(Kilograms Per Meter Squared) | Placebo | Levomilnacipran ER | SSRI | Total |
|---|---|---|---|---|
| Mean | 28.16 ± 4.85 | 28.61 ± 5.22 | 28.80 ± 5.10 | 28.51 ± 5.04 |
The record gives a start of Apr 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years 1 month after primary completion. A results delay was requested in Jul 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomilnacipran